Mergers & acquisitions
Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.
Fresh out of the gates with $500 million in financing, Neumora Therapeutics forged a partnership with Amgen to develop and commercialize assets for neurodegenerative diseases.
The deal, which includes an upfront payment of $1.75 billion, enables Boston Scientific to expand its electrophysiology and structural heart product portfolio.
Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.
Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.
Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
Investment firm Avoro Capital has raised concerns that the $180 per-share price Merck is paying Acceleron Pharma undervalues the rare-disease focused company.
Merck will acquire Acceleron for the expected $180 per share in cash for an approximate total equity value of $11.5 billion.
Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.
PRESS RELEASES